These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32267807)

  • 21. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments.
    Sasson C; Dieujuste N; Klocko R; Basrai Z; Celedon M; Hsiao J; Himstreet J; Hoffman J; Pfaff C; Malmstrom R; Smith J; Holstein A; Johnson-Koenke R
    Acad Emerg Med; 2023 Apr; 30(4):289-298. PubMed ID: 36757683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing the opioid crisis: An assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization.
    Kirane H; Drits E; Ahn S; Kapoor S; Morgenstern J; Conigliaro J; Enden J
    J Opioid Manag; 2019; 15(3):193-204. PubMed ID: 31343721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
    Fitzgerald Jones K; Khodyakov D; Arnold R; Bulls H; Dao E; Kapo J; Meier D; Paice J; Liebschutz J; Ritchie C; Merlin J
    JAMA Oncol; 2022 Aug; 8(8):1107-1114. PubMed ID: 35771550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why aren't physicians prescribing more buprenorphine?
    Huhn AS; Dunn KE
    J Subst Abuse Treat; 2017 Jul; 78():1-7. PubMed ID: 28554597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 34. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
    Kennedy-Hendricks A; Barry CL; Stone E; Bachhuber MA; McGinty EE
    Drug Alcohol Depend; 2020 Nov; 216():108217. PubMed ID: 32810837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
    James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
    Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and Management of Opioid Use Disorder in Primary Care: an Update.
    Donroe JH; Bhatraju EP; Tsui JI; Edelman EJ
    Curr Psychiatry Rep; 2020 Apr; 22(5):23. PubMed ID: 32285215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Making the business case for an addiction medicine consult service: a qualitative analysis.
    Priest KC; McCarty D
    BMC Health Serv Res; 2019 Nov; 19(1):822. PubMed ID: 31703741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department.
    Wiercigroch D; Hoyeck P; Sheikh H; Hulme J
    BMC Emerg Med; 2021 Apr; 21(1):48. PubMed ID: 33858328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.